Clinical Outcome of High Risk Gastrointestinal Stromal Tumor in a Meckel’s Diverticulum

Michele Scialpi¹, Christian Franzini², Antonio Cavaliere³, Francesco Barberini⁴, Irene Piscioli⁵, Ilaria Franceschetti⁶, Luciano Lupattelli¹

¹Department of Surgery Radiology, Odontostomatology Science, Section of Diagnostic and Interventional Radiology, University of Perugia, S. Maria della Misericordia Hospital, S. Andrea delle Fratte, 06156 Perugia, Italy; ²Division of Surgery, Guastalla Hospital, Via Donatori di Sangue 1, 40016 Guastalla (RE), Italy; ³Department of Anatomic Pathology, University of Perugia, Via Brunamonti 51, 06100 Perugia, Italy; ⁴Oncological Surgical Unit, University of Perugia, Via Brunamonti 51, 06100 Perugia, Italy; ⁵Department of Radiology, Budrio Hospital, Via Benni 44, 44054 Budrio (BO), Italy; ⁶Institute of Anatomic Pathology, S. Maria del Carmine Hospital, Piazzale S. Maria 6, 38068 Rovereto (TN), Italy

ABSTRACT

We describe a seven years follow-up of a high risk gastrointestinal stromal tumor in a Meckel’s diverticulum in a 68-year-old man with abdominal pain and vomiting. The patient was operated in emergency for peritonitis due to perforation of small intestine and treated with imatinib mesylate. The metastatic progression of the disease demonstrated the value of prognostic indicators (mitotic rate >10/50 high power field, necrosis and 8 cm in maximum diameter) for assessing risk of aggressive behaviour. Computed tomography was a valuable procedure for detection of local recurrence, the distant metastases and for surveillance after surgery in the follow-up. The review of the literature shows that this case has the longest follow up and consents the comparisons of the same neoplasm in other sites most frequent and better described than Meckel’s diverticulum. (Int J Biomed Sci 2009; 5 (1): 74-78)

Keywords: gastrointestinal stromal tumor; Meckel diverticulum; imatinib mesylate

INTRODUCTION

Gastrointestinal stromal tumors (GISTs) may be defined as mesenchymal tumors that express KIT protein or have an activating mutation in a class III receptor tyrosine kinase gene, the PDGFR-α gene, which encodes the platelet derived growth factor receptor-alpha, a tyrosine kinase protein. The KIT protein can be detected by immunohistochemical assays for the CD117 antigen (1).

Incidence of GISTs within the Meckel’s diverticulum (MD) is 0.5 to 3.2% (2, 3). To our knowledge, only six cases have been previously reported. Presenting symptoms, radiologic and clinical findings have been described, but not the behaviour of the disease (Table 1) (2-12).

We present the clinical outcome of a high risk GIST in a MD, treated with imatinib mesylate, with a follow-up of seven years, as a first example of “disease biologic progression model” suggested by prognostic indicators.

CASE REPORT

A 68-year-old man was referred to our institution in August 2001 because of abdominal pain and vomiting.
| Authors                              | Year/sex | Presentation symptoms                                      | Preoperative Radiology and Clinical Diagnosis                                      | Surgical Specimen and Histological Diagnosis | Follow up                      |
|-------------------------------------|----------|------------------------------------------------------------|------------------------------------------------------------------------------------|----------------------------------------------|---------------------------------|
| Johnston et al 2001 (2)            | 58/male. | 20 hours history of right iliac fossa pain.               | Abdominal and pelvic US: solid, hypoechoic, rounded mass lying anterior to the bifurcation of the aorta and indenting the dome of the bladder. The mass had an echobright posterior wall consistent with calcification. CT of the pelvis: pelvic mass adjacent to loops of bowel in the mesentery, with close relation to the bladder. PD: complicated mesenteric cyst or a soft tissue sarcoma arising in the mesentery. | 10 cm of small bowel containing the Meckel’s mass. | GIST not otherwise specified. |
| Stolk et al 2002 (3), Biemans & Vos 2005 (4) | 50/male. | Melena for 5 days, dispnea on exertion, nausea.           | Selective angiogram of branch of superior mesenteric artery: pathologic vascular configuration just cranial to urinary bladder. PD: MD or tumor. | MD with 5 cm ulcer-like mass. | Not reported.                  |
| Lorusso et al 2003 (5)             | 55/male. | Edema to the legs.                                         | Echo-color Doppler: femoro-iliac-caval-sorhepatic venous thrombosis. CT scan: 12 cm mass of small intestine and MD. Abdominal X-Ray: MD with stenosis and dilatation of the small intestine. | 3,5 in the MD. | GIST (positivity for CD117). |
| Hager et al 2005 (6)               | 75/male. | Not reported.                                              | Abdominal X-Ray: pneumoperitoneum PD: perforation of a hollow. | Excision of perforated MD with incomplete tumor resection. | Discharged 4 weeks after laparotomy because of postoperative complications. |
| Mijandrusic Sincic et al 2005 (7)  | 81/male. | 12 hours before the admission sudden colic pain, constipation, vomiting of fecal matter. | Abdominal X-Ray: dilated loops of intestine with large packers of gas. Abdominal ultrasound: distended bowel loops with anti-peristalsis. PD: iliac perforation. | 5 cm segment of small bowel with a polyposus tumor measuring 3 cm in diameter in a MD, 18 cm ileum, 20 cm cecum and ascending colon. | Discharged 13 days after admission. |
| Khoury II et al 2006 (8)           | 28/male. | Severe abdominal pain of increasing intensity, nausea, emesis. | CT with intravenous and oral contrast: a small bowel obstruction with a complex mass contiguous to the obstruction, which was cystic with enhancing soft tissue components. PD: MD. | 11.5 × 11 × 6.5 circumscribed mass arising from the MD wall. | Treatment with imatinib mesylate (outcome not specified). |
| Chandramohan et al 2007 (9)        | 65/male. | Constipation for 4 months and bleeding per rectum for one month. | Abdominal ultrasound: 6 × 9 cm exophytic hypoechoic lesion in the pelvis near sigmoid colon. Contrast enhanced CT scan: lobulated mass in pelvis compressing anterior wall of sigmoid colon and located posterosuperior to the urinary bladder. PD: small bowel tumor compressing sigmoid colon. | MD tumor with 3 cm of ileum, involving the anterior wall of sigmoid colon and part of the urinary bladder musculature. | Uneventful postoperative period. |
A plain X-ray of the abdomen showed distension of the small intestine and colon; no air-fluid levels or subphrenic free air was revealed.

Ultrasonography of the abdomen showed a voluminous (8 cm in maximum diameter) solid, heterogeneous, pelvic mass to the posterior side of the urinary bladder, probably arising from the small intestine (Fig. 1).

A moderate amount of free fluid in the right iliac fossa was revealed. As a result of the symptoms and radiological findings, preoperative diagnosis of peritonitis due to small intestine perforation and MD tumor with intratumoral necrosis was performed. The patient underwent an emergency surgical resection of the 4 cm ileum with MD neoplasm and lateral ileo-ileal anastomosis.

The surgical specimen showed a well-circumscribed mass, measuring 8 × 3 cm, arising from the MD wall.

The pathology report was of high risk GIST (mitotic rate >10/50 high power field, necrosis and 8 cm in maximum diameter) (Fig. 2). All margins were negative.

Twelve hours after surgery a fecal peritonitis due to perforation of the perianastomotic ileum was revealed.

A second surgical operation with latero-lateral ileo-ileo-anastomosis was performed.

After 10 days the patient was discharged in good condition. Abdominopelvic helical Computerized Tomography (CT), performed 8-months after surgery, revealed a voluminous mass (10.5 cm in maximum diameter) in the right iliac fossa and two contiguous masses of 10 cm and of 2.8 cm in maximum diameter in the pelvis.

On precontrast CT the masses were solid with heterogeneous content, well-defined margins and heterogeneous enhancement after intravenous contrast material administration (Fig. 3). No distant or lymph nodes metastases were revealed.

Table 1. (continued)

| References          | Age/gender | Clinical presentation | Imaging findings                                                                 | Pathological findings                                                                 |
|---------------------|------------|-----------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Komen et al 2007 (10) | 79/male    | Rectal bleeding       | Contrast enhanced CT scan: large, well-circumscribed mass in the left upper abdomen. | 14 cm mass arising from MD. GIST (CD117 positivity).                                   |
| Macaigne et al 2007 (11) | 66/female  | Rectal bleeding       | First surgery (1996): not reported. Second surgery (2004) CT scan: 12 × 10 × 7.5 cm, abdominal, polilobulated, heterogeneous mass between the intestine, extended to the subcutaneous tissue. Bone, liver, axillary and abdominal nodal metastases. | First surgery: 3 cm MD tumor. Ulcerated leiomyoma(1 mitose/50 HPF, CD34+) with retrospective diagnosis of GIST (positivity for CD117). Second surgery: surgical biopsy of the metastases (26/10 HPF, diffuse positivity for CD117, 50% positivity for CD34). Treatment with imatinib mesylate 2006: liver, nodal and peritoneal metastases. |
| De la Morena et al 2007 (12) | 47/female  | Severe abdominal pain, emesis. | Transvaginal ultrasound: 6.2 × 4.8 cm mass likely of ovarian origin. | MD tumor. GIST borderline (1 mitose/10 HPF, CD117 positive). Not evidence of disease five years after surgery. |

CT, computed tomography; HPF, high power field; MD, Meckel’s diverticulum; PD, preoperative diagnosis; US, ultrasound.

Figure 1. Pelvic ultrasound shows a 8 cm solid, heterogeneous, pelvic mass (arrow) to the posterior side of the urinary bladder.
The patient was treated with imatinib mesylate (400 mg/die for 4 weeks) and he did not present adverse effects to the therapy.

Abdominopelvic helical CT, performed 18 months after surgery, revealed marked reduction in size of the masses. The histology of these masses showed regressive features as fibrosis and necrosis due to the therapy with the tyrosine kinase inhibitors (Fig. 4).

Appearance and size of the lesions did not change on CT scans obtained 5-years after surgery.

In January 2008 the patient was referred to our institution because of fecal occult blood.

Abdominopelvic helical CT, showed increase in size (11 cm in maximum diameter) of the mass localized in the upper abdomen and multiple hepatic metastases. The abdominal and pelvic masses were resected. The histology showed a proliferative pattern of high risk GIST metastases.

The patient was discharged from the hospital 9 days after surgery.

**DISCUSSION**

Today, on the basis of the pathological and immunohistochemical features, most gastrointestinal mesenchymal tumors are classified as GISTs (13).

Since other mesenchymal tumors as leiomyosarcomas (14), fibrosarcomas (15) and not other specified stromal tumors arising from MD have been reported more frequently than GIST, probably the application of the new histological and immunohistochemical techniques could modify the original diagnosis.

In our case the outcome shows that the site is very important in determining the prognosis. Patients with a small bowel localization do worse than those with stomach GIST as reported by DeMatteo et al (16).

In a case of a MD localization, the treatment with imatinib mesylate has been reported by Khoury II et al (8), but the impact on the clinical behaviour of disease has not been described. In the present report the metastatic progression of disease demonstrated the value of prognostic indicators for assessing risk of aggressive behaviour of GIST also in MD, despite the small number of cases reported. Imatinib mesylate controlled the disease and for the first time we document the histological effects of the therapy.

CT is a valuable procedure for detection of local recurrence, distant metastases and for surveillance after surgery. If a localized recurrence is detected, the patient may be treated with repeated resection to prevent compli-
cations and to attempt a cure.

In conclusion, our case illustrated the first long-term follow-up in a high-grade GIST in MD and the histological features of the treatment with imatinib mesylate.

REFERENCES

1. Fletcher CD, Berman JJ, Corless C, Gorstein F, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum. Pathol. 2002; 33: 459-465.
2. Johnston AT, Khan A, Bleakney R, Keenan RA. Stromal tumor within a Meckel’s diverticulum: CT and ultrasound findings. Br. J. Radiol. 2001; 74: 1142-1144.
3. Stolk M, De Jong M, van Ramshorst B, Biemans JM, et al. Intestinal bleeding due to a stromal tumor in a Meckel’s diverticulum. Gastrointest Endosc. 2002; 56: 147-149.
4. Biemans JM, Vos JA. Bleeding stromal tumor in Meckel’s diverticulum. JBR-BTR. 2005; 88: 112-113.
5. Lorusso R, Forte A, Urbano V, Soda G, et al. Small bowel stromal tumors in a “meckelian” location. About a clinical observation. Ann. Ital. Chir. 2003; 74: 707-711.
6. Hager M, Maier H, Eberwein M, Klingler P, et al. Perforated Meckel’s diverticulum presenting as a gastrointestinal stromal tumor: a case report. J. Gastrointest Surg. 2005; 9: 809-811.
7. Mijandrusic Sincic B, Kovac D, Jasic M, Grbas H, et al. Crohn’s disease and a gastrointestinal stromal tumor in an 81-year-old man—a rare coincidence. Zentralbl. Chir. 2005; 130: 597-599.
8. Khoury MG, 2nd, Aulicino MR. Gastrointestinal stromal tumor (GIST) presenting in a Meckel’s diverticulum. Abdom Imaging. 2007; 32: 78-80.
9. Chandramohan K, Agarwal M, Gurjar G, Gatti RC, et al. Gastrointestinal stromal tumour in Meckel’s diverticulum. World J. Surg. Oncol. 2007; 5: 50-55.
10. Komen DJ, Kingma PJ, Gerrits MA, van Muiswinkel JM. An unusual cause of rectal bleeding. Neth. J. Med. 2007;65: 407-408.
11. Macaigne G, Boivin JF, Bellaiiche A, Auriault ML, et al. Retrospective diagnosis of stromal tumor with liver and nodal metastasis in a hemorrhagic Meckel’s diverticulum appearing 8 years after the first resection. Gastroenterol. Clin. Biol. 2007; 31: 1032-1035.
12. De la Morena López F, Fernández-Salazar L, Velayos B, Aller R, et al. Meckel’s diverticulum and gastrointestinal stromal tumor: an unusual association. Gastroenterol. Hepatol. 2007; 30: 534-537.
13. Rosa J. GIST: an update. Int. J. Surg. Pathol. 2003; 11: 177-186.
14. De Mulder RM, Verschave JG. Perforated leiomyosarcoma of Meckel’s diverticulum. Case report. Eur. J. Surg. 1991; 157: 69-70.
15. Calderale SM, Marchioni L, Malizia A, Riminucci M, et al. Malignant stromal tumor consistent with fibrosarcoma arising from Meckel’s diverticulum. Clinicopathological study of an incidentally discovered tumor and review of the literature. Tumori. 1997; 83 (3): 703-708.
16. Dematteo RP, Gold JS, Saran L, Gönen M, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008; 112 (3): 608-615.